ACHN Stock Zooms 17% as FDA Grants BTD for Danicopan

ACHN stock

ACHN stock is leading in the biotech sector after Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced that the FDA has granted Breakthrough Therapy Designation (BTD) for danicopan (ACH-4471).

Investors Cheer the News

When a pharmaceutical company releases highly encouraging information with regards to any of its medicines, then its stock is almost always bound to rally, and that is what happened this morning with Achillion Pharmaceuticals stock. Danicopan, or ACH-4471, is one of the most important medicines in the company’s pipeline and in a new development, the United States Food and Drugs Administration granted it the designation of ...

Read The Full Article On MicroSmallCap.com

Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.

All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.